ResearcherSeoul National UniversityActive in the last 2 years
Min Woo Lee
Matched on ORCID iD 0000-0003-3011-1425; OpenAlex author ID A5100768029. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2023: 1 paper · 2024: 2 papers
Papers 3
- Prognostic value of initial and longitudinal changes in body composition in metastatic pancreatic cancer. Co-author DOI 10.1002/jcsm.13437↗
- Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. Co-author DOI 10.4062/biomolther.2023.109↗
- Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers15092642↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sang Hyub Lee · 3 shared papers, 2023–2024 · strength 0.58
- Paper Prognostic value of initial and longitudinal changes in body composition in metastatic pancreatic cancer. DOI 10.1002/jcsm.13437↗
- Paper Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. DOI 10.4062/biomolther.2023.109↗
- Paper Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Panc… DOI 10.3390/cancers15092642↗
- Woo Hyun Paik · 2 shared papers, 2024 · strength 0.43
- J.H. Lee · 2 shared papers, 2023–2024 · strength 0.34
- Paper Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. DOI 10.4062/biomolther.2023.109↗
- Paper Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Panc… DOI 10.3390/cancers15092642↗
- Sang Kook Lee · 2 shared papers, 2023–2024 · strength 0.34
- Paper Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. DOI 10.4062/biomolther.2023.109↗
- Paper Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Panc… DOI 10.3390/cancers15092642↗
- Ja‐Lok Ku · 2 shared papers, 2023–2024 · strength 0.34
- Paper Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. DOI 10.4062/biomolther.2023.109↗
- Paper Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Panc… DOI 10.3390/cancers15092642↗
- Jin Ho Choi MD · 2 shared papers, 2023–2024 · strength 0.34
- Paper Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. DOI 10.4062/biomolther.2023.109↗
- Paper Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Panc… DOI 10.3390/cancers15092642↗
- Ji Kon Ryu · 2 shared papers, 2023–2024 · strength 0.34
- Paper Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. DOI 10.4062/biomolther.2023.109↗
- Paper Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Panc… DOI 10.3390/cancers15092642↗
- Yong‐Tae Kim · 2 shared papers, 2023–2024 · strength 0.34
- Paper Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. DOI 10.4062/biomolther.2023.109↗
- Paper Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Panc… DOI 10.3390/cancers15092642↗
- Ijin Joo · 1 shared paper, 2024 · strength 0.24
- Sun Kyung Jeon · 1 shared paper, 2024 · strength 0.24
- Jeong Hee Yoon · 1 shared paper, 2024 · strength 0.24
- Jeong Min Lee · 1 shared paper, 2024 · strength 0.24
- Dong‐Chan Oh · 1 shared paper, 2024 · strength 0.18
- In Rae Cho · 1 shared paper, 2024 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.